NASDAQ: ELYMEliem Therapeutics Inc Stock
$3.66-0.09 (-2.4%)
Updated Apr 24, 2024
ELYM Price
$3.66
Fair Value Price
$3.44
Market Cap
$101.45M
52 Week Low
$2.34
52 Week High
$5.19
P/E
-2.82x
P/B
0.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.12M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$21M
Beta
0.56
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ELYM Overview
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, develops therapies to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other for neuronal excitability disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 and ETX-155. The company also develops preclinical pipeline programs, such as the Kv7 Program and Anxiolytic. Eliem Therapeutics was incorporated in 2018 and is headquartered in Redmond, WA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELYM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELYM ($3.66) is overvalued by 6.48% relative to our estimate of its Fair Value price of $3.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELYM ($3.66) is not significantly undervalued (6.48%) relative to our estimate of its Fair Value price of $3.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELYM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELYM due diligence checks available for Premium users.
Be the first to know about important ELYM news, forecast changes, insider trades & much more!
ELYM News
Valuation
ELYM fair value
Fair Value of ELYM stock based on Discounted Cash Flow (DCF)
Price
$3.66
Fair Value
$3.44
Overvalued by
6.48%
ELYM ($3.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELYM ($3.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELYM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELYM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.82x
Industry
15.69x
Market
41.27x
ELYM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.94x
Industry
5.86x
ELYM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELYM's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
ELYM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$110.5M
Liabilities
$2.9M
Debt to equity
0.03
ELYM's short-term assets ($110.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELYM's short-term assets ($110.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELYM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$947.0k
Investing
$36.7M
Financing
$288.0k
ELYM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELYM vs Biotech Stocks
Eliem Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.